查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675301

2025 年至 2033 年 MRSA 药物市场按 MRSA 类型（医院获得性、社区获得性）、药物类别、疾病适应症、给药途径、配销通路和地区划分

MRSA Drugs Market by MRSA Type (Hospital-Acquired, Community-Acquired ), Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2024IMARC Group全球 MRSA 药物市场规模达到 39 亿美元。抗生素抗药性菌株的盛行率不断上升、由于住院时间延长而在医疗机构中不断接触耐多药菌以及临床试验数量的不断增加是推动市场发展的一些关键因素。

抗甲氧西林金黄色葡萄球菌 (MRSA) 是由抗生素抗药性金黄色葡萄球菌菌株引起的感染，通常发生在接受外科手术、接受静脉注射插管或皮肤接触的患者身上。 MRSA 药物是用来对抗抗甲氧西林金黄色葡萄球菌感染的抗菌剂，以杀死或抑制该细菌。它们抑制病原体的作用，同时增强患者的细胞合成和免疫力。最常见的 MRSA 药物包括甲氧芐啶-磺胺甲噁唑、克林霉素、米诺环素、利奈唑胺或强力霉素。这些药物一般为口服药，疗程一般为七至十天。 MRSA 感染可能源自医院或社区，因此 MRSA 的治疗有时可能涉及口服药物和静脉（IV）药物，这取决于病情的严重程度。目前有多种抗 MRSA 药物可用于治疗不同类型的感染，包括皮肤感染、骨骼感染、菌血症，甚至动物的人畜共通传染病。

MRSA 药品市场趋势：

抗生素抗药性菌株在人群中的日益普及是推动市场成长的重要因素。这可以归因于全球医院内感染（HAI）病例数量的增加。此外，由于长期住院，医疗机构中不断接触耐多药菌，导致继发性院内感染的发展，从而推动了市场的发展。此外，老年人口的不断增长使得他们更容易感染 MRSA，这也为市场的发展提供了动力。此外，人们对不同形式细菌感染的认识不断增强，导致 MRSA 药物的使用率更高。同时，大量的产品创新、越来越多的临床试验以及新型药物的推出正在为市场创造丰厚的成长机会。然而，开发新型 MRSA 药物变异所涉及的高成本正成为市场成长的主要限制因素。相反，各种诊断工具技术的不断发展，以及筛选抗生素抗药性菌株的临床试验计画数量的增加，正在创造积极的市场前景。主要参与者进行的广泛研究和开发 (R&D) 活动进一步推动了市场的发展。影响市场发展的其他因素包括针对现有产品的仿製药的出现、线上和线下组织平台上抗生素的便捷获取、快速的城市化以及医疗支出的增加。

本报告回答的关键问题：

  • 到目前为止，全球 MRSA 药物市场表现如何，未来几年将如何表现？
  • 全球 MRSA 药物市场的驱动因素、限制因素和机会有哪些？
  • 主要的区域市场有哪些？
  • 哪些国家是最具吸引力的 MRSA 药品市场？
  • 根据 MRSA 类型，市场分布如何？
  • 根据药品类别，市场如何划分？
  • 根据疾病指征，市场如何划分？
  • 根据行政路径，市场如何划分？
  • 根据配销通路，市场如何划分？
  • 全球 MRSA 药物市场的竞争结构是怎么样的？
  • 全球 MRSA 药物市场的关键参与者/公司有哪些？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球 MRSA 药品市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依 MRSA 类型

  • 医院获得性 (HA-MRSA)
  • 社区型 (CA-MRSA)

第 7 章：市场区隔：依药物类别

  • 脂肽类
  • 噁唑烷酮
  • 头孢菌素
  • 四环素
  • 叶酸拮抗剂
  • 其他的

第 8 章：市场区隔：依疾病适应症

  • 皮肤感染
  • 骨骼和关节感染
  • 菌血症
  • 动物感染

第九章：市场细分：依行政途径

  • 口服
  • 肠外给药

第 10 章：市场区隔：按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 11 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 12 章：驱动因素、限制因素与机会

  • 概述
  • 驱动程式
  • 限制
  • 机会

第 13 章：价值链分析

第 14 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 15 章：价格分析

第 16 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Basilea Pharmaceutica Ltd
    • Crystal Genomics Inc.
    • Cumberland Pharmaceuticals Inc
    • Melinta Therapeutics Inc
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc
Product Code: SR112025A6905

The global MRSA drugs market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.95% during 2025-2033. The rising prevalence of antibiotic resistant strains development, continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission and the growing number of clinical trials represent some of the key factors driving the market.

Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of staphylococcus aureus that generally occurs in patients who undergo surgical procedures, receive intravenous tubing, or come in contact with each other skin-to-skin. The MRSA drugs are used as antimicrobial agents against methicillin-resistant staphylococcus aureus infection in order to kill or restrain it. They inhibit the actions of pathogens while enhancing the patient's cellular synthesis and immunity. The most common MRSA drugs consist of trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, or doxycycline. These drugs are generally used as oral medication, usually on a course of seven to ten days. MRSA infections can arise from hospitals or from community, hence the treatment for MRSA can sometimes involve the administration of oral medications and intravenous (IV) medications, depending on the severity. There are a wide variety of MRSA drugs available that can be used for the treatment of different types of infections, including skin infections, bone infections, bacteremia, and even zoonotic infections in animals.

MRSA Drugs Market Trends:

The rising prevalence of antibiotic resistant strains development among the masses is a significant factor driving the growth of the market. This can be attributed to the increase in the number of cases of hospital-acquired infections (HAIs) on the global level. Also, the continual exposure to multidrug-resistant organisms in healthcare facilities due to prolonged hospital admission is resulting in the development of secondary nosocomial infections, thereby propelling the market. In addition to this, the growing geriatric population that is more susceptible to developing MRSA infections is providing an impetus to the market. Moreover, the augmenting awareness regarding different forms of bacterial infection is leading to a higher uptake of MRSA drugs. In line with this, numerous product innovations, growing number of clinical trials and the introduction of novel drug variants are creating lucrative growth opportunities in the market. However, the high costs involved in developing novel MRSA drug variants is acting as major growth restraining-factor for the market. On the contrary, continual technological developments in various diagnostic tools, along with the increasing number of clinical trial programs for the screening of antibiotic resistant strains of bacteria, are creating a positive market outlook. The market is further impelled by extensive research and development (R&D) activities conducted by the key players. Some of the other factors contributing to the market include the emergence of generic drugs against presently available products, easy availability of antibiotics across online and offline organized platforms, rapid urbanization, and increasing medical expenditure.

Key Market Segmentation:

MRSA Type Insights

  • Hospital-Acquired (HA-MRSA)
  • Community-Acquired (CA-MRSA)

Drug Class Insights

  • Lipopeptides
  • Oxazolidinones
  • Cephalosporin
  • Tetracycline
  • Folate Antagonist
  • Others

Disease Indication Insights

  • Skin Infections
  • Bone and Joint Infections
  • Bacteremia
  • Animal Infections

Route of Administration Insights

  • Oral Administration
  • Parenteral Administration

Distribution Channel Insights

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for MRSA drugs. Some of the factors driving the North America MRSA drugs market include the rising medical expenditure, the increasing number of clinical trial programs, extensive research and development (R&D) activities conducted by key players, etc.
  • Competitive Landscape
  • The report has also provided a comprehensive analysis of the competitive landscape in the global MRSA drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AbbVie Inc., Basilea Pharmaceutica Ltd, Crystal Genomics Inc., Cumberland Pharmaceuticals Inc., Melinta Therapeutics Inc, Paratek Pharmaceuticals, Inc., Pfizer Inc, etc.

Key Questions Answered in This Report:

  • How has the global MRSA drugs market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global MRSA drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive MRSA drugs markets?
  • What is the breakup of the market based on the MRSA type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the disease indication?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the competitive structure of the global MRSA drugs market?
  • Who are the key players/companies in the global MRSA drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global MRSA Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by MRSA Type

  • 6.1 Hospital-Acquired (HA-MRSA)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Community-Acquired (CA-MRSA)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Lipopeptides
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oxazolidinones
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cephalosporin
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Tetracycline
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Folate Antagonist
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Disease Indication

  • 8.1 Skin Infections
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Bone and Joint Infections
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Bacteremia
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Animal Infections
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral Administration
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral Administration
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

  • 12.1 Overview
  • 12.2 Drivers
  • 12.3 Restraints
  • 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica Ltd
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
    • 16.3.3 Crystal Genomics Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
    • 16.3.4 Cumberland Pharmaceuticals Inc
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Melinta Therapeutics Inc
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Paratek Pharmaceuticals, Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Pfizer Inc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: MRSA Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: MRSA Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: MRSA Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: MRSA Drugs Market: Breakup by MRSA Type (in %), 2024
  • Figure 5: Global: MRSA Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: MRSA Drugs Market: Breakup by Disease Indication (in %), 2024
  • Figure 7: Global: MRSA Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: MRSA Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: MRSA Drugs Market: Breakup by Region (in %), 2024
  • Figure 10: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: MRSA Drugs (Hospital-Acquired (HA-MRSA)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: MRSA Drugs (Community-Acquired (CA-MRSA)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: MRSA Drugs (Lipopeptides) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: MRSA Drugs (Lipopeptides) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: MRSA Drugs (Oxazolidinones) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: MRSA Drugs (Oxazolidinones) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: MRSA Drugs (Cephalosporin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: MRSA Drugs (Cephalosporin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: MRSA Drugs (Tetracycline) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: MRSA Drugs (Tetracycline) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: MRSA Drugs (Folate Antagonist) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: MRSA Drugs (Folate Antagonist) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: MRSA Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: MRSA Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: MRSA Drugs (Skin Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: MRSA Drugs (Skin Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: MRSA Drugs (Bone and Joint Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: MRSA Drugs (Bone and Joint Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: MRSA Drugs (Bacteremia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: MRSA Drugs (Bacteremia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: MRSA Drugs (Animal Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: MRSA Drugs (Animal Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: MRSA Drugs (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: MRSA Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: MRSA Drugs (Parenteral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: MRSA Drugs (Parenteral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: MRSA Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: MRSA Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: MRSA Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: MRSA Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: MRSA Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: MRSA Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: North America: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: North America: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: United States: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: United States: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Canada: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Canada: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Asia-Pacific: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Asia-Pacific: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: China: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: China: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Japan: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Japan: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: India: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: India: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: South Korea: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: South Korea: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Australia: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Australia: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Indonesia: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Indonesia: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Europe: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Europe: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Germany: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Germany: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: France: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: France: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: United Kingdom: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: United Kingdom: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Italy: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Italy: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Spain: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Spain: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Russia: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Russia: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Latin America: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Latin America: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Brazil: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Brazil: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Mexico: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Mexico: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Others: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Others: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Middle East and Africa: MRSA Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Middle East and Africa: MRSA Drugs Market: Breakup by Country (in %), 2024
  • Figure 92: Middle East and Africa: MRSA Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Global: MRSA Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 94: Global: MRSA Drugs Industry: Value Chain Analysis
  • Figure 95: Global: MRSA Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: MRSA Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: MRSA Drugs Market Forecast: Breakup by MRSA Type (in Million USD), 2025-2033
  • Table 3: Global: MRSA Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: MRSA Drugs Market Forecast: Breakup by Disease Indication (in Million USD), 2025-2033
  • Table 5: Global: MRSA Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: MRSA Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: MRSA Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: MRSA Drugs Market: Competitive Structure
  • Table 9: Global: MRSA Drugs Market: Key Players